HIV/SIV Replication In Vivo

$1,757,804ZIAFY2017AINIH

National Institute Of Allergy And Infectious Diseases

Investigators

Linked publications & trials

Paper 37349337 Paper 35551291 Paper 35264559 Paper 34986348 Paper 34562096 Paper 33600506 Paper 32966579 Paper 32866318 Paper 32690707 Paper 31473167 Paper 31139193 Paper 31004012 Paper 30980067 Paper 30943274 Paper 30787294 Paper 30686586 Paper 30619267 Paper 30420858 Paper 30388160 Paper 30364428 Paper 30352254 Paper 30081906 Paper 29997288 Paper 29911997 Paper 29911996 Paper 29785023 Paper 29781814 Paper 29664020 Paper 29498807 Paper 29444938 Paper 29364886 Paper 29325070 Paper 29237774 Paper 29029583 Paper 28580437 Paper 28539448 Paper 28431010 Paper 28289286 Paper 28133794 Paper 27453467 Paper 27367521 Paper 26581981 Paper 26223303 Paper 25858157 Paper 25197078 Paper 24321564 Paper 23847057 Paper 23739328 Paper 23482645 Paper 22398371 Paper 21116997 Paper 21115690 Paper 19876388 Paper 19698967 Paper 19656883 Paper 19339347 Paper 19000013 Paper 18947296 Paper 17913821 Paper 16809286 Paper 16709858 Paper 15994779 Paper 15967828 Paper 15479838 Paper 14976381 Paper 14764689 Paper 14722271 Paper 12648460 Paper 12524385 Paper 12167680 Paper 11986671

Abstract

HIV is known to replicate primarily in activated CD4+ T cells. In addition, HIV can remain silent in unactivated T cells - what is referred to as the latent reservoir. Because current anti-retroviral agents only target actively replicating virus, the existance of a latent reservoir is the primary reason why current strategies do not eliminate HIV from people. This study seeks to define the subsets of CD4+ T cells in patients that contain HIV - in both active and latent forms - as a basis to develop strategies to eliminate HIV from the body.

View original record on NIH RePORTER →